Diversified Trust Co bought a new position in shares of Edwards Lifesciences Corp (NYSE:EW) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,852 shares of the medical research company’s stock, valued at approximately $209,000.
A number of other large investors have also modified their holdings of EW. State of Alaska Department of Revenue boosted its position in shares of Edwards Lifesciences by 376.8% in the fourth quarter. State of Alaska Department of Revenue now owns 24,625 shares of the medical research company’s stock valued at $2,774,000 after acquiring an additional 19,460 shares during the period. Syntal Capital Partners LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $315,000. Schwab Charles Investment Management Inc. boosted its position in shares of Edwards Lifesciences by 4.1% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 723,832 shares of the medical research company’s stock valued at $81,584,000 after acquiring an additional 28,821 shares during the period. First National Trust Co boosted its position in shares of Edwards Lifesciences by 77.8% in the fourth quarter. First National Trust Co now owns 16,298 shares of the medical research company’s stock valued at $1,837,000 after acquiring an additional 7,134 shares during the period. Finally, Creative Planning boosted its position in shares of Edwards Lifesciences by 1.7% in the fourth quarter. Creative Planning now owns 33,354 shares of the medical research company’s stock valued at $3,759,000 after acquiring an additional 573 shares during the period. Hedge funds and other institutional investors own 81.61% of the company’s stock.
EW has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 26th. Barclays restated an “equal weight” rating and issued a $120.00 price objective on shares of Edwards Lifesciences in a research report on Saturday, September 30th. Canaccord Genuity restated a “buy” rating and issued a $155.00 price objective on shares of Edwards Lifesciences in a research report on Sunday, October 8th. Cowen restated a “buy” rating and issued a $135.00 price objective on shares of Edwards Lifesciences in a research report on Thursday, October 12th. Finally, SunTrust Banks set a $124.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a research report on Wednesday, October 25th. Six analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Edwards Lifesciences currently has a consensus rating of “Buy” and an average target price of $129.57.
Shares of Edwards Lifesciences Corp (EW) opened at $123.91 on Friday. The firm has a market cap of $26,220.00, a P/E ratio of 36.02, a P/E/G ratio of 1.95 and a beta of 0.51. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.49 and a quick ratio of 2.76. Edwards Lifesciences Corp has a one year low of $86.55 and a one year high of $124.10.
Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.02). The company had revenue of $821.50 million during the quarter, compared to analysts’ expectations of $833.85 million. Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.68 earnings per share. equities analysts anticipate that Edwards Lifesciences Corp will post 3.76 EPS for the current fiscal year.
Edwards Lifesciences declared that its board has approved a stock repurchase program on Thursday, December 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.
ILLEGAL ACTIVITY WARNING: This article was reported by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3148518/1852-shares-in-edwards-lifesciences-corp-ew-purchased-by-diversified-trust-co.html.
About Edwards Lifesciences
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.